Press Release: TherOx : TherOx Receives FDA Approval for First Heart Attack Treatment Since PCI to Reduce Infarct Size

IRVINE, Calif.--(BUSINESS WIRE)-- TherOx, Inc., a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its SuperSaturated Oxygen (SSO2) Therapy. SSO2 Therapy provides interventional cardiologists with the first and only FDA-approved treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in heart attack patients.